Prenatal Diagnosis and Genetic Analysis of 21q21.1–q21.2 Aberrations in Seven Chinese Pedigrees

Huamei Hu†, Rong Zhang†, Yongyi Ma, Yanmei Luo, Yan Pan, Juchun Xu, Lupin Jiang* and Dan Wang*

Department of Gynecology and Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China

Background: Chromosomal aberrations contribute to human phenotypic diversity and disease susceptibility, but it is difficult to assess their pathogenic effects in the clinic. Therefore, it is of great value to report new cases of chromosomal aberrations associated with normal phenotypes or clinical abnormalities.

Methods: This was a retrospective analysis of seven pedigrees that carried 21q21.1–q21.2 aberrations. G-banding and single-nucleotide polymorphism array techniques were used to analyze chromosomal karyotypes and copy number variations in the fetuses and their family members.

Results: All fetuses and their family members showed normal karyotypes in seven pedigrees. Here, it was revealed that six fetuses carried maternally inherited 21q21.1–q21.2 duplications, ranging from 1 to 2.7 Mb, but none of the mothers had an abnormal phenotype. In one fetus, an 8.7 Mb deletion of 21q21.1–q21.2 was found. An analysis of the pedigree showed that the deletion was also observed in the mother, brother, and maternal grandmother, but no abnormal phenotypes were found.

Conclusion: This study identified 21q21.1–q21.2 aberrations in Chinese pedigrees. The carriers of 21q21.1–q21.2 duplications had no clinical consequences based on their phenotypes, and the 21q21.1–q21.2 deletion was transmitted through three generations of normal individuals. This provides benign clinical evidence for pathogenic assessment of 21q21.1–q21.2 duplication and deletion, which was considered a variant of uncertain significance and a likely pathogenic variant in previous reports.

Keywords: 21q21.1–q21.2 duplication, 21q21.1–q21.2 deletion, SNP array, NCAM2, prenatal diagnosis

INTRODUCTION

To date, the 21q21 duplication and deletion have not been included in the known pathogenicity syndromes. However, early in the 1980s, Park et al. reported that partial trisomy of chromosome 21, comprising the NCAM2 gene, results in intellectual disability but does not cause other phenotypes of Down syndrome (DS) (Park et al., 1987). Haldeman-Englert et al. revealed that a boy who was evaluated for autistic features, significant speech delay, and poor social interactions carried a de novo 8.8 Mb 21q21.1–q21.3 deletion involving...
the NCAM2 gene (Haldeman-Englert et al., 2009). In addition, three cases of neurodevelopmental disorders were reported, with clinical phenotypic abnormalities including global developmental delay, behavioral disorders, and impaired social interactions. All of them carried 21q21.1–21.2 deletions involving NCAM2 (Petit et al., 2015). Another case report revealed that a boy with autism spectrum disorder and macrocephaly carried a 1.6 Mb deletion of 21q21.1–21.2, containing the NCAM2 gene, but no other functional gene (Scholz et al., 2016). Previously, NCAM2 was proposed as a candidate gene for autism based on genome-wide association studies (Hussman et al., 2011). Duplications, deletions, and single-nucleotide polymorphisms of the NCAM2 gene have been found in individuals with intellectual disabilities or autism, and these studies suggest that NCAM2 might play a role in neurodevelopmental disorders.

In our study, the carriers of 21q21.1–21.2 duplications in six pedigrees (the region of one pedigree contained NCAM2) showed normal phenotypes. We further identified a rare 8.7 Mb deletion of 21q21.1–21.2 containing NCAM2, which had been transmitted through three generations of normal individuals. These findings provide benign evidence, which is important for accurate genetic counseling on 21q21.1–21.2 aberrations in prenatal diagnosis.

MATERIALS AND METHODS

Subjects
A retrospective study was performed from January 2016 to December 2020. In total, seven cases carrying 21q21.1–21.2 deletions or duplications were selected from 11,867 pregnant women who had indications (e.g., abnormal non-invasive prenatal testing (NIPT) or fetal imaging) and underwent invasive diagnostic testing via amniocentesis or cordocentesis at the Prenatal Diagnosis Center of Obstetrics and Gynecology, Southwest Hospital. Informed consent for invasive prenatal diagnosis was obtained from the parents before detection. This research was approved by the Ethics Committee of Southwest Hospital, Third Military Medical University (Army Medical University). Six fetuses from six unrelated Chinese families were identified as carrying 21q21.1–q21.2 duplications, as their pedigree verification information was collected, and they were classified as pedigrees 1, 2, 3, 4, 5, and 6. In addition, a fetus carrying a 21q21.1–q21.2 deletion and its family members were labeled as pedigree 7. The pregnant women in these seven pedigrees did not have pregnancy complications and denied any related family history.

Pedigrees 1–6: The maternal age at the time of amniocentesis was between 25 and 32 years, and a gestational age ranging from 18 + 2 to 25 weeks. The pregnant woman in pedigree 3 chose amniocentesis because of pulmonary sequestration of the fetus examined by ultrasound. The others all chose amniocentesis because NIPT screening showed an abnormality on chromosome 21. Pedigree 7: A 22-year-old woman (gravida 4, para 1) was subjected to cordocentesis at 26 + 5 gestational weeks because the bilateral ventricle of the fetus had widened, as tested by ultrasound examination (left: 14 mm, right: 14 mm).

Chromosomal Karyotyping
Approximately 0.5 ml of each peripheral blood sample and 0.4 ml of each umbilical cord blood sample were inoculated into a T-cell culture medium (BAIDI, China) and incubated at 37°C, for 3 days. Approximately 20 ml of each amniotic fluid sample was inoculated into an amniotic fluid medium (BIO-AMF™-2, BI, China) and incubated at 37°C, with 5% CO₂, for 7–10 days. Chromosomal karyotyping was performed according to the standard protocol using G-banding at a 400-banded (amniotic fluid samples) or 550-banded (blood samples) resolution, and karyotypes were described according to the International System for Human Cytogenetic Nomenclature 2016 (ISCN 2016) criteria (Stevens-Kroef et al., 2017).

Single-Nucleotide Polymorphisms Array Analysis
Uncultured amniotic fluid samples (10 ml per fetus), umbilical cord blood samples (600 µL per fetus), and peripheral blood (600 µL per person) of the pedigree members were collected, and DNA was extracted using the TIANamp Genomic DNA Kit (TIANGEN, China). The Infinium Global Screening Array (Illumina, San Diego, CA, United States) contains approximately 700,000 genome-wide tag SNPs. Genomic DNA was hybridized to an Infinium Global Screening Array as reported previously (Srebniak et al., 2011). The array was scanned with the iScan array scanning system (Illumina, San Diego, CA, United States). Molecular karyotype analysis was performed using GenomeStudio V2011.1 software (Illumina, San Diego, CA, United States), which was used for annotation. Copy number variations (CNVs) that were larger than 100 kb or affected more than 50 markers were considered and were annotated based on the GRCh37 (hg19) genome. CNVs were evaluated according to the guidelines (Richards et al., 2015; Riggs et al., 2020), scientific literature, and publicly available databases as follows: DGV (http://dgv.tcag.ca/dgv/app/home), OMIM (http://www.ncbi.nlm.nih.gov/omim), gnomAD (http://gnomad-sg.org/), DECIPHER (http://decipher.sanger.ac.uk), dbVar (http://www.ncbi.nlm.nih.gov/dbvar), ClinVar (http://www.ncbi.nlm.nih.gov/clinvar), ClinGene (https://www.ncbi.nlm.nih.gov/projects/dbvar/clinvar), and Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/). Benign or likely benign CNVs were not reported.

Prenatal and Postnatal Follow-Up Assessment
Ultrasound results of the second and third trimesters of pregnancy were collected. Postnatal clinical follow-up
assessments via telephone were performed from 6 months to 3 years after birth. After obtaining their parents’ informed consent, the child’s healthcare data were collected to assess developmental details. General child healthcare was carried out by professional doctors according to the World Health Organization’s physical and mental development table for infants aged 0–3 years. Child healthcare in tertiary hospitals was performed according to the Denver Developmental Screening Test (Wijedasa, 2012).

RESULTS

Analysis of the Chromosomal Karyotype of the Fetuses and Family Members

Amniotic fluid samples, umbilical cord blood samples, and peripheral blood samples of family members were subjected to conventional karyotyping because balanced rearrangements will escape SNP array detection (Levy and Wapner, 2018).

Pedigrees 1–6: The conventional G-banding analysis showed that the karyotypes of the fetuses and their parents were normal.

Pedigree 7: Although typical karyotypic analysis by G-banding might be able to delineate chromosomal aberrations greater than 5–10 Mb in size (Shaffer and Beijani, 2004), the 8.7 Mb deletion of 21q21.1–21.2 was not identified in our study. Owing to the small size of chromosome 21, the deletion region could only be identified above 700-banded resolution, whereas the conventional amniotic karyotyping could only achieve 550-banded resolution at most. Therefore, the fetus (III:2, Figure 1), its elder brother (III:1, Figure 1), mother (II:2, Figure 1), and maternal grandmother (I:2, Figure 1) had normal karyotypes. Its father (II:1, Figure 1) and maternal grandfather (I:1, Figure 1) also had normal karyotypes.

Verification of SNP Array Results of the Fetuses and Family Members

Pedigrees 1–6: The fetuses of six unrelated pedigrees carried the 21q21.1–q21.2 duplications, which were inherited from their mothers, and with the same coordinates and lengths as those of their mothers. The smallest duplication length was 1 Mb (chr21:20,195,657–21,199,532, hg19 build), and the largest was 2.7 Mb (chr21:23,573,580–26,310,725, hg19 build). The duplicated regions in pedigrees 1, 2, 3, 5, and 6 did not contain any protein-coding gene, and only the duplication in pedigree 4 contained the NCAM2 gene (Table 1; Figure 2; Supplementary Figure S1). All fathers were also tested with SNP arrays, and the results were negative.

Pedigree 7: SNP array results showed that the fetus (III:2, Figure 1) carried an 8.7 Mb deletion of chromosome 21q21.1–21.2 (chr21:16,767,983–25,441,375, hg19 build; Figure 2; Supplementary Figure S1), and the pedigree analysis found that the CNV was inherited from the mother with a normal phenotype (II:2, Figure 1). To obtain more genetic evidence, the elder brother and maternal grandparents of the fetus were also tested with SNP arrays. The extended analysis of the pedigree revealed that two other healthy members also carried the deletion, the elder brother, 3 years of age (III:1, Figure 1), and maternal grandmother, 41 years of age (I:2, Figure 1). In addition, the results of others (II:1 and I:1, Figure 1) in this pedigree were normal. Otherwise, the elder brother was found to carry another deletion, which was located on 5p15.33 (chr5:19,38,139–1,124,703, hg19 build) and was proven to be a de novo variation of uncertain significance (VUS) mutation. No other significant CNVs were found among the seven pedigrees.

Prenatal and Postnatal Follow-Up Assessment

Pedigrees 1–6: No abnormalities were found during the second and third trimesters of pregnancy, except for the fetuses in pedigree 3 with pulmonary isolation. Three boys (fetuses of pedigrees 1, 3, and 6) and three girls (fetuses of pedigrees 2, 4, and 5) were born at full-term delivery. Now, the youngest individual is 2.5 years of age, the oldest is 3.5 years of age, and none of them show signs of developmental delay or intellectual disability based on child’s healthcare examination (Table 2).
Pedigree 7: Ultrasound and MRI examinations were performed at 32 weeks of gestation, and no further widening of the lateral ventricles was observed in both examinations (left: 14 mm, right: 14 mm, examined by ultrasound; left: 12.5 mm, right: 13.6 mm, examined by MRI). After genetic counseling, the pregnant woman and her husband chose to continue the pregnancy. A healthy boy was born by natural delivery at 39 gestational weeks, without any special facial features. The boy is 8 months old currently and does not have any abnormal phenotypes; moreover, the details of the child’s healthcare examination were normal (Table 2). His elder brother is 3 years of age and also does not show developmental delay or intellectual disability.

**DISCUSSION**

We reported seven fetuses carrying familial 21q21.1–q21.2 aberrations. The fetuses of pedigrees 1, 2, 3, 4, 5, and 6 all carried a maternally inherited 21q21.1–q21.2 duplication ranging from 1 to 2.7 Mb (Table 1). There are few reports about whether the duplication of this region is benign or pathogenic. In public databases such as DGV, gnomAD, DECIPHER, dbVar, and ClinVar, several significant records of 21q21.1–q21.2 duplications were found, which partially overlapped with our cases, and they were analyzed (Figure 2; Table 3). Only three records were recorded in DGV (dgv4402n100) and the gnomAD database (nsv4279387, nsv4532854), but the frequency of copy number gains in the general population had not been described. In addition, a case with intellectual disability had been reported (DECIPHER, #256222), but there is no description about its inheritance and classification of pathogenicity. Another case (DECIPHER, #331844) was described as a likely benign variant with no abnormalities other than increased nuchal translucency. A VUS variant (nsv995050) was found in the dbVar and the ClinVar database, and the major phenotype was

| Pedigree | Location (hg19) | Size (Mb) | Aberration type | Karyotype | Protein-coding gene content | Inheritance |
|----------|----------------|-----------|----------------|-----------|-----------------------------|-------------|
| Pedigree 1 | chr21: 20,195,657–21,199,532 | 1 | Duplication | 46,XY | — | mat |
| Pedigree 2 | chr21:23,573,580–24,697,989 | 1.1 | Duplication | 46,XX | — | mat |
| Pedigree 3 | chr21: 23,288,789–25,106,099 | 1.8 | Duplication | 46,XY | — | mat |
| Pedigree 4 | chr21: 22,734,409–25,148,429 | 2.4 | Duplication | 46,XX | NCAM2 | mat |
| Pedigree 5 | chr21:23,272,300–25,104,945 | 1.8 | Duplication | 46,XX | — | mat |
| Pedigree 6 | chr21: 23,573,580–26,310,725 | 2.7 | Duplication | 46,XY | — | mat |
| Pedigree 7 | chr21: 16,767,983–25,441,375 | 8.7 | Deletion | 46,XY | BTG3, C21orf91, CHODL, CXADR, NCAM2, TMPRSS15, USP25 | mat |

*mat, Inherited from the mother.*
developmental delay. Therefore, duplication of this region was considered a VUS in previous reports. The 21q21.1–q21.2 duplication in our study contained only one protein-coding gene, NCAM2, which is not predicted to be a triplosensitive gene. Jin et al. reported that a fetus and its mother both carried a 6.7 Mb duplication of 21q21.1–q21.2 including NCAM2, but

| Fetus | Sex | At birth | Birth with other defects | Routine child healthcare (6 m, 12 m, 24 m) | Child healthcare by DDST | At study |
|-------|-----|----------|--------------------------|------------------------------------------|-------------------------|----------|
| 1     | Male| 3.3 (46) | 51 (72.2) | Pass                         | NA NA                  | 42       |
| 2     | Female | 3.3 (56) | 50 (67.7) | Pass                         | Pass NA                | 41       |
| 3     | Male | 3.06 (26.8) | 50 (52.4) | Pulmonary sequestration Pass | NA NA                | 41       |
| 4     | Female | 3.3 (56) | 50 (67.7) | Pass                         | NA NA                  | 37       |
| 5     | Female | 3.5 (71.6) | 51 (83.9) | Pass                         | NA NA                | 33       |
| 6     | Male  | 3 (23.3) | 48 (15.9) | Pass                         | NA Pass               | 32       |
| 7     | Male  | 2.35 (1.1) | 48 (15.9) | Pass                         | NA NA                | 8        |

m, months; NA, not available; percentile refers to WHO, Growth Charts.

| Patient database | Location (hg19) | Type | Size (Mb) | Protein-coding gene | Inheritance | Pathogenicity | Phenotypes |
|------------------|----------------|------|-----------|----------------------|-------------|---------------|------------|
| dbVar#nsv995050 | chr21: 21,601,231–22,573,421 | Duplication | 972 kb | NCAM2 | Unknown | VUS | Developmental delay and/or other significant developmental or morphological phenotypes, intellectual disability |
| Decipher#256222 | chr21: 20,063,479–22,274,948 | Duplication | 2.2 Mb | — | Inherited from a normal parent | / | Intellectual disability |
| Decipher#331844 | chr21: 22,782,651–24,339,651 | Duplication | 1.6 Mb | NCAM2 | Inherited from the father | Likely benign | Increased nuchal translucency |
| Decipher#276325 | chr21: 22,434,634–26,315,434 | Deletion | 3.8 Mb | NCAM2 | Inherited from the affected mother | / | Behavioral abnormality, delayed speech and language development |
| Decipher#327587 | chr21: 20,746,935–24,883,731 | Deletion | 3.9 Mb | NCAM2 | Unknown | / | Overweight, recurrent otitis media, sandal gap, abnormal oral glucose tolerance, acanthosis nigricans, generalized non-motor (absence) seizure, generalized-onset seizure, simple febrile seizure, status epilepticus |
| dbVar#nsv531520 | chr21: 21,699,837–26,771,050 | Deletion | 5.1 Mb | NCAM2 | Inherited from the mother | Pathogenic | Abnormality of the skeletal system, cleft palate, global developmental delay |
| dbVar#nsv534303 | chr21: 16,714,035–24,198,636 | Deletion | 7.5 Mb | BTG3, C21orf91, CHD11, CXADR, NCAM2, TMPRSS15, USP25 | Unknown | Pathogenic | Oral cleft |
| Decipher#254181 | chr21: 16,992,255–24,898,237 | Deletion | 7.9 Mb | BTG3, C21orf91, CHD11, CXADR, NCAM2, TMPRSS15, USP25 | Inherited from the mildly affected father | / | Epicanthic folds, long and flat philtrum, high palate, low-set ears, global developmental delay, behavioral disorder |
| Decipher#274603 | chr21: 17,451,703–25,948,154 | Deletion | 8.5 Mb | BTG3, C21orf91, CHD11, CXADR, NCAM2, TMPRSS15 | Unknown | / | Almond-shaped eyes, hypotonia and joint laxity, global developmental delay, impaired social interactions |

/., not provided by database.
the phenotype was normal. The region was significantly larger than that of our cases (ranging from position 18,981,715 to 25,707,009). This study also provided benign clinical evidence for partial duplication of 21q21.1–q21.2 in prenatal diagnosis (Jin et al., 2021). The rarity of gene content might be a major factor that makes these CNV gains, shown in this study, seem benign. In addition, position effects are one of the molecular mechanisms responsible for CNVs caused by genomic rearrangements resulting in phenotypes (Zhang et al., 2009). Whether the pathogenicity can change if the chromosomal duplication is not in its original position but translocates to another chromosome requires further study.

The pathogenicity of the copy-number gain and copy-number loss might be quite different in the same region. A copy-number loss record involving NCAM2 was found in the DGV database (nsv821690, Figure 2), but the frequency in the general population had not been described. Several cases of phenotypic abnormalities related to 21q21.1–21.2 deletions, and those highly overlapping with our case, were found in the public databases (Figure 2, Table 3). The sizes of these regions were approximately 4 Mb or greater. Three cases (Decipher#276325, Decipher#254181, and Decipher#274603), provided by Petit et al., their inheritance, and phenotypes had been described in detail (Petit et al., 2015). In five cases (Table 3), the deletion involved only NCAM2, and patients had abnormal phenotypes including those concerning intellectual disability, developmental delay, abnormal facial shape, and seizures. In two cases (nsv531520 and 534303), one was reported to have an abnormality of the skeletal system, cleft palate, and global developmental delay, and another had an oral cleft. They were all described as pathogenic, of which only one CNV (nsv531520) was inherited from the mother, but no information was provided about her phenotype. In summary, the 21q21.1–21.2 deletion was identified as likely pathogenic in previous reports. However, the 21q21.1–21.2 deletion in our study was not found to be associated with phenotypic consequences.

Previous and recent studies have revealed the important role of NCAM2 in neurodevelopment (Sheng et al., 2019). In addition to NCAM2, there are other genes associated with clinical phenotypes in this region that deserve further analysis. This region contains seven protein-coding genes, namely, BTG3, C21orf91, CHODL, CXADR, NCAM2, TMPRSS15, and USP25. None of them are predicted to be haploinsufficient. Except for C21orf91, others are Online Mendelian Inheritance in Man (OMIM) genes. BTG3 is a novel member of the PC3/BTG/TOB family of growth inhibitory genes (Yoshida et al., 1998) and is expressed in various human tissues. Further analysis in mice revealed that BTG3 is highly expressed in the ventricular zone of the developing central nervous system. C21orf91 was described as having a role in defective DS neurogenesis (Li et al., 2016) and plays an important role in accurate oligodendroglial differentiation, affecting maturation capacity and axon myelination (Reiche et al., 2021). CHODL is a type-1A integral membrane protein and is preferentially expressed in the skeletal muscle, testis, brain, and lung (Weng et al., 2003). A recent study showed that the absence of CHODL leads to anatomical and functional defects of the neuromuscular synapse (Oprişoreanu et al., 2019). CXADR is expressed at increased levels during brain development and is considered a candidate gene in children with autism (Iourov et al., 2010). Patients carrying 21q21.1 microduplication (from 0.4 to 0.1 Mb) involving the CXADR gene have abnormal phenotypes such as developmental delay and intellectual disability (Li et al., 2018). TMPRSS15 is a morbid gene, and loss-of-function variants are responsible for enterokinase deficiency (Wang et al., 2020). It is well known that USP25 is widely expressed in the central nervous system and peripheral nervous system (Bosch-Comas et al., 2006). Recent studies have shown that USP25 plays a key role in microglial homeostasis reprogramming in Alzheimer’s disease and DS (Zheng et al., 2021). Therefore, BTG3, C21orf91, CXADR, NCAM2, and USP25 might be involved in phenotypes based on their presumed or known biological functions.

The mechanism through which aberrations do not produce clinical phenotypes is unclear. Genetic counseling in this region has become challenging, owing to limited or conflicting associations with clinical phenotypes described in the published literature and public databases. Accordingly, our study provides benign evidence for accurate genetic counseling of 21q21.1–21.2 aberrations based on prenatal diagnosis.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ebi.ac.uk/ena/browser/view/PRJEB47787.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of Southwest Hospital, Third Military Medical University (Army Medical University). The number is (B)KY2021023. Written informed consent to participate in this study was provided by the participant’s legal guardian/next of kin.
AUTHOR CONTRIBUTIONS

HH designed the study and wrote the article, RZ performed chromosome analysis, YM performed sample processing and data analysis, YL performed data statistical, YP performed follow-up, JX performed cell culture, LJ proofread the paper and acquired funding, and DW performed project administration.

FUNDING

This work was supported by the grant from the National Natural Science Foundation of China (No. 81971369 to LJ).

REFERENCES

Bosch-Comas, A., Lindsten, K., González-Duarte, R., Masucci, M. G., and Marfany, G. (2006). The ubiquitin-specific protease USP25 Interacts with Three Sarcomeric Proteins. Cell. Mol. Life Sci. 63, 723–734. doi:10.1007/s00018-005-533-1

Haldeman-Englert, C. R., Chapman, K. A., Kruger, H., Geiger, E. A., McDonald-mcginn, D. M., Rappaport, E., et al. (2009). De Novo 8.8-Mb Deletion of 21q21.1-q21.3 in an Autistic Male with a Complex Rearrangement Involving Chromosomes 6, 10, and 21. Am. J. Med. Genet. 152A (10), 196–202. doi:10.1002/ajmg.a.33176

Hussman, J. P., Chung, R.-H., Griswold, A. J., Jaworski, J. M., Salyakina, D., Ma, D., et al. (2015). 21q21 Deletion Involving NCAM2: Report of 3 Cases with Partial Duplication 21q21.1-q21.2 with normal Phenotype Maternally. Eur. J. Med. Genet. 11, 201–212. doi:10.1016/j.ejmg.2018.01.005

Iourov, I. Y., Vorsanova, S. G., Saprina, E. A., and Yurov, Y. B. (2010). Identification of Candidate Genes of Autism on the Basis of Molecular Cytogenetic and In Silico Studies of the Genome Organization of Chromosomal Regions Involved in Unbalanced Rearrangements. Russ. J. Genet. 46, 1190–1193. doi:10.1134/S102279541010011X

Jin, C., Gu, Z., Jiang, X., Yu, P., and Xu, T. (2021). A Prenatal Diagnosis Case of Partial Duplication 21q21.1-q21.2 with normal Phenotype Maternally Inherited. BMC Med. Genomics 14, 4–8. doi:10.1186/s12920-021-01013-x

Levy, B., and Wapner, R. (2018). Prenatal Diagnosis by Chromosomal Microarray Analysis. Fertil. Sterility 109, 201–212. doi:10.1016/j.fertnstert.2018.01.005

Li, S. S., Qu, Z., Haas, M., Ngo, L., Heo, Y. J., Kang, H. J., et al. (2016). The HSA21 Gene EURL/C21ORF91 Controls Neurogenesis within the Cerebral Cortex and Is Implicated in the Pathogenesis of Down Syndrome. Sci. Rep. 6, 1–14. doi:10.1038/rep29514

Li, W., Wang, X., and Li, S. (2018). Investigation of Copy Number Variations on Chromosome 21 Detected by Comparative Genomic Hybridization (CGH) Microarray in Patients with Congenital Anomalies. Mol. Cytogenet. 11, 1–8. doi:10.1186/s13039-018-0391-3

Oprpisoreanu, A.-M., Smith, H. L., Arya, S., Webster, R., Zhong, Z., Eaton-Hart, C., et al. (2019). Interaction of Axonal Chondrolectin with Collagen XIa1 Is Necessary for Precise Neuromuscular Junction Formation. Cell Rep. 29, 1082–1098. doi:10.1016/j.celrep.2019.09.033

Park, J. P., Wurster-Hill, D. H., Andrews, P. A., Cooley, W. C., and Graham, J. M. (1987). Free Proximal Trisomy 21 without the Down Syndrome. Clin. Genet. 32, 342–348. doi:10.1111/j.1399-0004.1987.tb02399.x

Petit, F., Plessis, G., Decamp, M., Cuisset, J.-M., Blyth, M., Pendlebury, M., et al. (2015). 21q21 Deletion Involving NCAM2: Report of 3 Cases with Neurodevelopmental Disorders. Eur. J. Med. Genet. 58, 44–46. doi:10.1016/j.ejmg.2014.11.004

Reiche, L., Gottle, P., Lane, L., Dued, P., Park, M., Azim, K., et al. (2021). C21orf91 Regulates Oligodendrogial Precursor Cell Fate: A Switch in the Glial Lineage? Front. Cel. Neurosci. 15, 1–18. doi:10.3389/fncel.2021.653075

AUTHOR CONTRIBUTIONS

HH designed the study and wrote the article, RZ performed chromosome analysis, YM performed sample processing and data analysis, YL performed data statistical, YP performed follow-up, JX performed cell culture, LJ proofread the paper and acquired funding, and DW performed project administration.

ACKNOWLEDGMENTS

We thank Dr. Limeng Dai for his advice on the article and grammar modification.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.731815/full#supplementary-material

Supplementary Figure 1 | Single-nucleotide polymorphism (SNP) array results for the fetuses, Pedigrees 1–6: 21q21.1–21.2 duplications, with fragment sizes in the following order: 1 Mb, 1.1 Mb, 1.8 Mb, 2.4 Mb, 1.8 Mb, and 2.7 Mb. Pedigree 7: 21q21.1–21.2 deletion; the fragment size was 8.7 Mb.

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015). Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424. doi:10.1038/gim.2015.30

Riggs, E. R., Andersen, E. F., Cherry, A. M., Kantarci, S., Kearney, H., Patel, A., et al. (2020). Technical Standards for the Interpretation and Reporting of Constitutional Copy-Number Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet. Med. 22, 245–257. doi:10.1038/s41436-019-0686-8

Scholz, C., Steinemann, D., Mälzer, M., Roy, M., Arslan-Kirchner, M., Illig, T., et al. (2016). NCAM2 Deletion in a Boy with Macrocephaly and Autism: Cause, Association or Predisposition? Eur. J. Med. Genet. 59, 493–498. doi:10.1016/j.ejmg.2016.08.006

Shaffer, L. G., and Beijani, B. A. (2004). A Cytogeneticist’s Perspective on Genomic Microarrays. Hum. Reprod. Update 10, 221–226. doi:10.1093/humupd/dmh022

Sheng, L., Leshchyn’ska, I., and Sytynk, V. (2019). Neural Cell Adhesion Molecule 2 (NCAM2)-Mediated Cell Adhesion Leads to Alteration of Cell-to-Cell Communication and Impairment of Neurite Outgrowth and Guidance in Autism. Mol. Autism 2, 1. doi:10.1186/s13229-021-00113-x

Wang, L., Zhang, D., Fan, C., Zhou, X., Liu, Z., Zheng, B., et al. (2020). Novel Compound Heterozygous TMPPS15 Gene Variants Cause Enterokinase Deficiency. Front. Genet. 11, 1–9. doi:10.3389/fgene.2020.538778

Weng, L., Hübler, R., Claessens, A., Smits, P., Wauters, J., Tylzanowski, P., et al. (2003). Isolation and Characterization of Chondrolectin (Chodl), a Novel C-Type Lectin Predominantly Expressed in Muscle Cells. Gene 308, 21–29. doi:10.1016/S0378-1119(03)00425-6

Wijedasa, D. (2012). Developmental Screening in Context: Adaptation and Standardization of the Denver Developmental Screening Test-II (DDST-II) for Sri Lankan Children. Child. Care Health Dev. 38, 889–899. doi:10.1111/j.1365-2224.2011.01332.x

Zheng, Q., Li, G., Wang, S., Zhou, Y., Liu, K., Gao, Y., et al. (2021). Trisomy 21-induced Disregulation of Microglial Homeostasis in Alzheimer’s
Brains Is Mediated by USP25. *Sci. Adv.* 7, 1–13. doi:10.1126/sciadv.abe1340

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Hu, Zhang, Ma, Luo, Pan, Xu, Jiang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.